Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Gamma-aminobutyric acid (GABA)-mediated inhibition is the primary mechanism by which neuronal excitability is reduced in the central nervous system. It involves the action of GABA on GABAA and GABAB receptors. GABAA receptors are ionotropic receptors that mediate fast inhibition through chloride ion influx, while GABAB receptors are metabotropic receptors that mediate slower, more prolonged inhibition through potassium channel activation and calcium channel inhibition. This inhibitory process is crucial for maintaining the balance between excitation and inhibition in the brain, preventing hyperexcitability, and regulating various neurological functions.
Enhancement of GABAergic neurotransmission via increased chloride ion conductance (GABAA receptors) or activation of potassium channels and inhibition of calcium channels (GABAB receptors).
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Gamma-Aminobutyric Acid-Mediated Inhibition (GABAergic Inhibition).